Specific in Vivo Deletion of B-cell Subpopulations Expressing Human Immunoglobulins by the B-cell Superantigen Protein L
Overview
Affiliations
Some pathogens have evolved to produce proteins, called B-cell superantigens, that can interact with human immunoglobulin variable regions, independently of the combining site, and activate B lymphocytes that express the target immunoglobulins. However, the in vivo consequences of these interactions on human B-cell numbers and function are largely unknown. Using transgenic mice expressing fully human immunoglobulins, we studied the consequences of in vivo exposure of protein L of Peptostreptococcus magnus with human immunoglobulins. In the mature pool of B cells, protein L exposure resulted in a specific reduction of splenic marginal-zone B cells and peritoneal B-1 cells. Splenic B cells exhibited a skewed light-chain repertoire consistent with the capacity of protein L to bind specific kappa gene products. Remarkably, these two B-cell subsets are implicated in innate B-cell immunity, allowing rapid clearance of pathogens. Thus, the present study reveals a novel mechanism that may be used by some infectious agents to subvert a first line of the host's immune defense.
Curto P, Barro A, Almeida C, Vieira-Pires R, Simoes I mBio. 2021; 12(6):e0305921.
PMID: 34872352 PMC: 8649778. DOI: 10.1128/mBio.03059-21.
A B-Cell Superantigen Induces the Apoptosis of Murine and Human Malignant B Cells.
Lorenzo D, Duarte A, Mundinano J, Berguer P, Nepomnaschy I, Piazzon I PLoS One. 2016; 11(9):e0162456.
PMID: 27603942 PMC: 5014328. DOI: 10.1371/journal.pone.0162456.
Kim D, To R, Kandalaft H, Ding W, van Faassen H, Luo Y MAbs. 2014; 6(1):219-35.
PMID: 24423624 PMC: 3929445. DOI: 10.4161/mabs.26844.
In vivo VL-targeted microbial superantigen induced global shifts in the B cell repertoire.
Gronwall C, Kosakovsky Pond S, Young J, Silverman G J Immunol. 2012; 189(2):850-9.
PMID: 22696444 PMC: 3598568. DOI: 10.4049/jimmunol.1200245.
Marginal zone B-cells, a gatekeeper of innate immunity.
Zouali M, Richard Y Front Immunol. 2012; 2:63.
PMID: 22566852 PMC: 3341996. DOI: 10.3389/fimmu.2011.00063.